Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Goes Public with $101.6M Offering

NEW YORK (GenomeWeb) – Invitae has launched its initial public offering at $16 per share.

The San Francisco-based molecular diagnostics firm offered 6,350,000 shares of its common stock, bringing in gross proceeds of $101.6 million. It also has granted the underwriters a 30-day option to purchase up to an additional 952,500 shares.

The offering price is above a range of $13 to $15 per share put forth in a preliminary prospectus filed two weeks ago. It also increased the number of shares offered from a previous expectation of 5,350,000.

Invitae plans to use between $24 million and $28 million of the proceeds for research and development; between $23 million and $27 million for marketing and sales; between $4 million and $6 million for capital expenditures, such as additional lab space and equipment; and the remainder for corporate and administrative expenses.

Invitae said previously that it plans to expand the number of genes it sequences for its tests from 216 to 500 this year. The firm noted in its amended filing that its test volume "has grown rapidly since commercial launch with over 2,000 billable tests delivered as of September 30, 2014. In addition, we delivered over 1,800 billable tests in the fourth quarter of 2014." But it also cautioned that it expects its testing business to grow more slowly prior to the expansion of the assay.

JP Morgan Securities is the sole book-running manager on the offering, while Cowen and Co. and Leerink Partners are acting as co-managers.

Invitae's shares began trading today on the New York Stock Exchange under the symbol "NVTA" and were up 8 percent at $17.27 Thursday morning.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.